As a result, the medication may not deliver the expected therapeutic benefits, such as supporting blood sugar control or weight management
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
When taken before or during your workout, BCAAs have been shown to: Improve endurance during training Increase strength during workouts Enhance recovery and reduce post-workout soreness Stimulate muscle protein synthesis Each of the three BCAAs offers unique benefits: Leucine triggers muscle protein synthesis, making it the most anabolic of the three
Other recognised side effects include fatigue, dizziness, headache, and injection site reactions
Some industry watchers believe the rising use of GLP-1 medication will have a "structural" impact on the market
Does This Make the Antibiotic Less Effective
